Literature DB >> 20739221

Rheumatoid arthritis progression mediated by activated synovial fibroblasts.

Elena Neumann1, Stephanie Lefèvre, Birgit Zimmermann, Steffen Gay, Ulf Müller-Ladner.   

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial hyperplasia and progressive joint destruction. Rheumatoid arthritis synovial fibroblasts (RASFs) are leading cells in joint erosion and contribute actively to inflammation. RASFs show an activated phenotype that is independent of the inflammatory environment and requires the combination of several factors. Although new aspects regarding RASF activation via matrix degradation products, epigenetic modifications, inflammatory factors, Toll-like receptor (TLR) activation and others have recently been uncovered, the primary pathophysiological processes in early arthritis leading to permanent activation are mostly unknown. Here, we review new findings regarding RASF activation and their altered behavior that contribute to matrix destruction and inflammation as well as their potential to spread RA.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20739221     DOI: 10.1016/j.molmed.2010.07.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  121 in total

Review 1.  Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases.

Authors:  Christian M Hedrich; George C Tsokos
Journal:  Trends Mol Med       Date:  2011-08-30       Impact factor: 11.951

2.  Genetics: a new interpretation of genetic studies in RA.

Authors:  Michel Neidhart; Emmanuel Karouzakis
Journal:  Nat Rev Rheumatol       Date:  2014-02-25       Impact factor: 20.543

3.  Autophagy inhibitor regulates apoptosis and proliferation of synovial fibroblasts through the inhibition of PI3K/AKT pathway in collagen-induced arthritis rat model.

Authors:  Shu Li; Jin-Wei Chen; Xi Xie; Jing Tian; Cong Deng; Jia Wang; Hai-Na Gan; Fen Li
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

4.  SIRT6 regulates the cigarette smoke-induced signalling in rheumatoid arthritis synovial fibroblasts.

Authors:  Anna Engler; Fabienne Niederer; Kerstin Klein; Renate E Gay; Diego Kyburz; Giovanni G Camici; Steffen Gay; Caroline Ospelt
Journal:  J Mol Med (Berl)       Date:  2014-03-19       Impact factor: 4.599

5.  Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.

Authors:  D C Hammell; L P Zhang; F Ma; S M Abshire; S L McIlwrath; A L Stinchcomb; K N Westlund
Journal:  Eur J Pain       Date:  2015-10-30       Impact factor: 3.931

Review 6.  Emerging cell and cytokine targets in rheumatoid arthritis.

Authors:  Gerd R Burmester; Eugen Feist; Thomas Dörner
Journal:  Nat Rev Rheumatol       Date:  2013-11-12       Impact factor: 20.543

7.  Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients.

Authors:  Dalia El-Lebedy; Jihan Hussein; Ingy Ashmawy; Asmaa M Mohammed
Journal:  Clin Rheumatol       Date:  2016-10-03       Impact factor: 2.980

8.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

9.  Hypermethylation of EBF3 and IRX1 genes in synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  Sung-Hoon Park; Seong-Kyu Kim; Jung-Yoon Choe; Youngho Moon; Sungwhan An; Mae Ja Park; Dong Sun Kim
Journal:  Mol Cells       Date:  2013-02-26       Impact factor: 5.034

10.  The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels.

Authors:  Elizabeth Olivares-Martínez; Diego F Hernández-Ramírez; Carlos A Núñez-Álvarez; Antonio R Cabral; Luis Llorente
Journal:  Clin Rheumatol       Date:  2015-08-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.